Importantly, this approach holds promise not only for tumor suppression, but also for overcoming resistance to small-molecule inhibitors of the ERK and PI3K/AKT/mTOR pathways (16) that are being tested in numerous ongoing clinical trials (ClinicalTrials.gov), a strategy supported by the ability of DT-061 to enhance 4E-BP1 expression and activity in the presence of ERK and mTOR inhibitors. Here, AKT1 is linked to neoplasm.